Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabiralizumab in PVNS/dt-TGCT
NL-OMON47675Phase 2Active, not recruiting
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabiralizumab in tenosynovial giant cell tumor (TGCT) (4 arms), sponsored by Five Prime Therapeutics, Inc. Primary endpoints: Dose-limiting toxicities in Phase 1 and Objective response rate in Phase 2. Started Nov 2015; status: active, not recruiting.
02
Drugs
cabiralizumab
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NL-OMON47675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47675.